



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

May 24, 2023

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- BIOCON
--	--

Dear Sir/Madam,

Subject: Investor Presentation – Q4 FY23.

With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**


Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: Investor Presentation



Q4 FY23 Investor Presentation


May 2023



Meta morphosis

Biocon 5.0

Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high-quality, affordable therapies that can lower costs, increase access and improve treatment outcomes.



Biocon at a Glance



**₹ 11,550 Cr |
\$ ~1.4 bn**
Revenue*



~15,000+
Total Employees*



Rank #8
Among Top 10 Global
Biotech Employers**



1,300+
Patents*



100+
cGMP approvals from
International regulatory agencies



7
Manufacturing
units*



120+
Countries where our
products are
available*



15 of top 20
pharma companies
served by service
portfolio *



Top 28
Products within
portfolio***

* Revenue numbers for FY23, others numbers as of FY22, ** 2022 Ranking by Science Magazine, *** As per IQVIA MIDAS Oct'22 MAT, top 50 molecules by revenue

Building Biocon



From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally



Generics Business at a Glance



Presence in
100+
countries including U.S.,
Europe & large EMs



5
State-of-the-art
facilities



90+
cGMP approvals
received from international
regulatory agencies



R&D team of
450+
scientists



750+
global
customer reach



Portfolio comprises
50+ APIs
75+ Generic
formulations



90+
Generic
formulation
dossiers
submitted



500+
DMFs filed in various
jurisdictions



300+
patents obtained

Strengths built over the years

- Expertise in fermentation technology, large scale chromatography & synthetic chemistry
- Leveraging in-house API to forward integrate and move up the value chain
- Balanced portfolio across therapeutic segments

Product Portfolio Expansion

- API - Expanding portfolio beyond fermentation and synthetic molecules to peptides, high potent APIs
- Formulations – Complex injectables, device dependent products, potent oral solids, modified-release and extended-release oral solids
- Augmenting portfolio through in-licensing strategy

Capacities Additions & Expansion

- Immunosuppressants API (Visakhapatnam)
- Other Fermentation APIs (Bengaluru)
- Peptides (Bengaluru)
- Synthetic API (Hyderabad)
- Injectables (Bengaluru)

Business Development initiatives

- Strategic partnerships with select customers
- Local manufacturing mandate opportunities in global markets - Technology transfer/ API supply / finished dosage formulations
- API: Expansion of business in key select markets
- Formulations: Expand commercial footprint beyond U.S, either directly or through partners

Other initiatives

- Continued focus on cost improvement and quality compliance
- De-risk critical intermediates sources
- Digital transformation initiatives to support key strategic priorities
- Focus on ESG initiatives like use of renewable energy, promoting gender diversity (incl. women in the shop-floor)

Generics : Our Key APIs and Formulations

APIs *

Therapeutic Area	Molecule	Therapeutic Area	Molecule
Cardiovascular	Apixaban	Immunosuppressants	Tacrolimus
	Atorvastatin		Mycophenolate Mofetil
	Dabigatran		Mycophenolate Sodium
	Fluvastatin		Everolimus
	Ivabradine		Tacrolimus
	Pravastatin		Pimecrolimus
	Rivaroxaban		Dasatinib
	Rosuvastatin		Everolimus
	Simvastatin		Lenalidomide
	Lovastatin		Temsirolimus
Anti-fungal	Sacubitril Sodium	Oncology	Micafungin
	Liraglutide		Anidulafungin
	Dapagliflozin		Posaconazole
Anti-Diabetics	Empagliflozin	Multiple Sclerosis	Fingolimod
	Linagliptin		Teriflunomide
	Repaglinide	Others	Orlistat
	Sitagliptin		Deferasirox
	Vildagliptin		Brinzolamide
	Pioglitazone		Mirabegron
			Fidaxomicin

FORMULATIONS

Therapeutic Area	Molecule	US	Dev. Markets: ex-US	MoW ¹
Cardiovascular	Rosuvastatin Calcium		EU	
	Simvastatin			
	Atorvastatin			
	Pravastatin			
	Labetalol HCl			
	Prazosin			
Oncology	Everolimus		EU ^{\$}	
	Pemetrexed	TA		
	Lenalidomide	TA	EU ^{\$}	
Immunosuppressants	Tacrolimus			
	Mycophenolic Sodium			
Multiple Sclerosis	Fingolimod			
	Teriflunomide			
Others	Aminocaproic acid (Antifibrinolytic)			
	Dapagliflozin (Anti Diabetic)	TA		
	Esomeprazole DR (Gastrointestinal)			
	Dorzolamide (Ophthalmic)			
	Posaconazole (Anti-Fungal)		UK, EU ^{\$}	
	Vigabatrin Oral Solution (CNS)			
	Vigabatrin Tablets (CNS)			

Launched
 Approved

* Filed DMFs | 1 MoW - Most of the World markets | ^{\$}Select EU countries | TA – Tentative approval

Biosimilars Business at a Glance



Global reach in
100+
countries including U.S.,
Europe and EMs



Top 15
in global
biomanufacturing
capacity



25+
cGMP approvals
received from key regulatory
agencies



Diverse global
talent pool of
5,500+
people



965+
patents granted



Portfolio comprises
20 biosimilars




8
Commercial
Products in Global
Markets



>5M
Patients served

Unique, fully integrated leading global biosimilars player

Biosimilars: Unique, fully integrated capabilities from lab to market



¹Two products are in-licensed i.e. Adalimumab & Etanercept

Built on a 40+ year legacy of cutting-edge science

- **Invested >\$1B in biosimilars ahead of its peers** to build expertise across multiple platforms and a differentiated portfolio - including insulins, mAbs and fusion proteins
- **In-house R&D, clinical and regulatory capabilities** to develop high precision biosimilars for global markets
- **Expertise in large scale manufacturing**, across Drug Substance, Drug Product and Devices and among the **Top 15 globally** in biomanufacturing **capacity**
- **Commercial reach in 100+ markets** through a combination of direct presence¹, strategic partnerships and distributors


...with a strong track record in an attractive market

- **Achieved many 'firsts' in the industry** - first to receive bTrastuzumab, bPegfilgrastim and interchangeable bGlargine approval in the US
- **Commercialized products in key Advanced Markets**, such as the US, EU, Japan and **several Emerging Markets** (e.g., India, Brazil, UAE, etc.)
- **Backed by marquee investors** including Tata Capital, True North, Goldman Sachs, ADQ and Viatris
- Biosimilars are an **attractive market** with FY22 addressable of \$25B², growing to **\$78B in FY28²**

Committed to enabling affordable access to high quality biosimilars globally

¹ Through the acquisition of Viatris' biosimilars business | ² Only includes products where there has been company reported sales; Biosimilar sales only included for companies that report the numbers








Biosimilars: Acquisition of Viatrix' global biosimilars business



Transformational deal to create value for all stakeholders

Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars




Therapy Area	Oncology 	Immunology 	Ophthalmology 	Bone Health 	Diabetes 	Others 	Vaccines 
Approved or Commercial	<ul style="list-style-type: none"> • Pegfilgrastim • Trastuzumab • Bevacizumab 	<ul style="list-style-type: none"> • Adalimumab • Etanercept 			<ul style="list-style-type: none"> • RHI • Glargine U100 • Aspart 		
Late Stage¹	<ul style="list-style-type: none"> • Denosumab • Pertuzumab 	<ul style="list-style-type: none"> • Ustekinumab 	<ul style="list-style-type: none"> • Aflibercept 	<ul style="list-style-type: none"> • Denosumab 			Several Infectious Disease Vaccines e.g. Malaria
Early Stage²	2 undisclosed assets	3 undisclosed assets			<ul style="list-style-type: none"> • Glargine U300 	2 undisclosed assets	

New product launches planned almost every year through 2030

1. Clinical to BLA Review; 2. Pre-Clinical

Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth

BIOCON BIOLOGICS GROWTH DRIVERS



Biocon Biologics' portfolio targets a ~US\$ 78 Billion addressable market by FY28

Note: Market size only includes products where there has been company reported sales; Biosimilar sales only included for companies that report the numbers

Pushing to deliver impactful innovations in collaboration with Equillium Inc.



Itolizumab

World's first novel humanized anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway

Biocon's second global 'lab to market' novel biologic after Nimotuzumab

Launched in India in 2013 to treat chronic plaque psoriasis under the brand ALZUMAb™

Licensed out rights to develop & commercialize in the U.S., Canada, Australia and New Zealand to U.S.-based biotechnology company, Equillium Inc. in 2017

Option and Purchase Agreement entered between Equillium and Ono Pharmaceutical Co., Ltd, Japan, where Equillium has granted Ono the exclusive right to acquire its rights to itolizumab

Acute Graft-Versus-Host Disease (GVHD)

- ✓ Pivotal Phase III Study initiated in Mar '22 for use in First-Line treatment of Acute GVHD; patient dosing initiated
- ✓ European Commission granted Orphan Drug Designation for treatment of aGVHD in Jul '21
- ✓ Received Fast Track designation from the US FDA

Systemic Lupus Erythematosus/ Lupus Nephritis (SLE/LN)

- ✓ Received Fast Track designation from the US FDA
- ✓ Given positive trends in Part A, expanded Part B portion of Phase 1b EQUALISE study to clinical centers in India
- ✓ Topline data expected in the first half of 2024

Cytokine Release Syndrome treatment in 'Moderate to Severe' Acute Respiratory Distress Syndrome

- ✓ Repurposed for prevention & treatment of COVID-19 complications in India in 2020
- ✓ Granted 'Restricted Emergency Use' approval in Sep '20

Ulcerative Colitis

- ✓ Application for Phase 2 clinical trials in India for the treatment of ulcerative colitis using Itolizumab, approved by the DCGI
- ✓ Initiated Phase 2 clinical study of itolizumab in patients with ulcerative colitis in Dec '22

The precision of targeted therapies | The power of tumor modulators



BCA101

(Formerly FmAb2)

Lead candidate

First-in-class EGFR / TGF β -trap bifunctional antibody

BCA 101

- ✓ Lead product candidate, **BCA101** (EGFR / TGF- β -trap) demonstrates tumor target engagement and clinical activity
 - ✓ **Monotherapy activity** in difficult to treat post-pembro squamous lung cancer
 - ✓ Activity in combination with pembro in **checkpoint and cetuximab-refractory** head and neck cancer (HNSCC) and anal canal cancer
- ✓ BCA101 + pembrolizumab combination dose expansion study **currently enrolling in 1L HNSCC – achieved efficacy threshold for Stage 1 prior to completing enrollment**

Organization

- ✓ Highly experienced management team, board of directors and advisory board
- ✓ \$82M raised in Seed/Series A from syndicate of dedicated biotech investors
- ✓ \$105M raised in Series B funding. Biocon ownership at 38%, to reduce to ~23% in FY24.
- ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience in CMC/drug development

Platform

- ✓ ToTeM™ – leverages rational combinations to unleash the full potential of targeted tumor modulators
- ✓ Pragmatic antibody engineering and manufacturable IgG-like biologics
- ✓ Delivering 2 additional INDs in 2023-2024

*a US based clinical-stage biotechnology company. In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.

Research Services :

Syngene's broad capabilities, spanning the value chain, facilitate integration to capture additional benefits for clients

Research business

Discovery Services



Flexible Platform with capability across multiple modalities, including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

SynVent Syngene's proprietary platform for Integrated Drug Discovery

SARchitect- Syngene's proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies

Dedicated R&D Centres



Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated, multi-disciplinary team of scientists

Access to entire Syngene ecosystem for specialist research and development operations

Development and Manufacturing business

Development Services



Pre-clinical to clinical trials

Drug substance and drug product development for both large and small molecules

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services



Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the-art API manufacturing and biologics manufacturing facilities

Research Services (Syngene) : Key Growth Levers



Opportunities for service integration in Discovery Services

- Flexible platform solutions with capabilities across multiple modalities for functional services
- Integrated Drug Discovery through SynVent Platform
- Leverage existing and new scientific capabilities
- Continuous capacity addition



Solutions-based approach in Development Services and clinical supplies

- Integrated Solutions from process development, clinical manufacturing to regulatory filing
- Increase capacity utilization in clinical manufacturing
- Capability additions through Injectable Fill Finish
- Operational efficiency through automation, digitalization



Scaling up Manufacturing Services

- Syngene's commercial manufacturing Services capability is new compared to the research services
- Completes the integrated platform offering to innovators across small molecule and Biologics



Extension and expansion of Dedicated Centres

- Reaffirms its reliability as a strong partner
- Contract with BMS extended till 2030
- Contract with Amgen extended till 2026



**Q4 & Full Year
FY23 Highlights**

Financial Highlights: Q4 FY23

Consolidated (in ₹ Cr.)	Q4 FY23	Q4 FY22	YoY %	
Total Revenue	3,929	2,476	59	Biosimilars +114% Research +31% Generics - Includes ₹109 Cr from Bicara stake dilution gain
Core EBITDA¹	1,260	809	56	Growth driven by Biosimilars & Research services
<i>% Margin</i>	35%	33%		
EBITDA	1,152	659	75	Net R&D spend at ₹342 Cr, up ₹152 Cr vs Q4 FY22, representing 12% of revenues ex-Syngene
<i>% Margin</i>	29%	27%		
Profit Before Tax <i>(Before exceptional charge)</i>	500	384	30	Increase in depreciation, amortization and interest expense primarily related to acquisition of Viatrix' biosimilar business
<i>% Margin</i>	13%	15%		
Net Profit <i>(Before exceptional charge)</i>	335	262	28	Increase in minority interest due to dilution of shareholding in Syngene and Biocon Biologics on account of the Viatrix deal
Net Profit Margin %	9%	11%		

¹ Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark-to-market movement on financial instruments

Financial Highlights: FY23 (1/2)

Consolidated (in ₹ Cr.)	FY23	FY22	YoY %	
Total Revenue	11,550	8,397	38	Biosimilars +61% Research +23% Generics +13% Includes ₹217 Cr from Bicara stake dilution gain
Core EBITDA¹	3,807	2,669	43	Growth driven by Biosimilars & Research services
<i>% Margin</i>	34%	32%		
EBITDA	2,888	2,183	32	Net R&D spend at ₹1,119 Cr, up ₹524 Cr vs FY22, representing 14% of revenues ex-Syngene Forex Loss of ₹160 Cr vs. gain of ₹58 Cr last year.
<i>% Margin</i>	25%	26%		
Profit Before Tax <i>(Before exceptional charge)</i>	1,189	1,094	9	Increase in depreciation, amortization and interest expense primarily related to acquisition of Viatris' biosimilar business
<i>% Margin</i>	10%	13%		
Net Profit <i>(Before exceptional charge)</i>	787	722	9	Increase in minority interest due to dilution of shareholding in Syngene and Biocon Biologics on account of the Viatris deal
Net Profit Margin %	7%	9%		

¹ Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark-to-market movement on financial instruments

Financial Highlights: FY23 (2/2)

Consolidated (in ₹ Cr.)	FY23	FY22	YoY %	
Net Profit <i>(before exceptional charge)</i>	787	722	9	Exceptional items during FY23: <ul style="list-style-type: none"> Deal related expenses of the Viatris transaction MAT credit balance charge on adoption of new tax regime of 25%
Exceptional Items <i>(net of tax and minority interest)</i>	(324)	74		
Net Profit / (loss) <i>(Reported)</i>	463	648		

Generics: Q4 & full year FY23 Update

KEY HIGHLIGHTS

- Revenue growth for the quarter muted mainly due to product mix, margins lower due to price erosion in base business products
- Delivered revenue in-line with guidance of for the full year driven by API sales, namely from immunosuppressants and specialty APIs and higher volume market share of recently launched generic formulation products in the U.S.
- Validation of the immunosuppressant API facility in Visakhapatnam and peptide facility in Bengaluru expected to be completed by H1 FY24.
- Made 32 filings and received 19 approvals for our generic formulation products across U.S., EU, UK, and emerging markets
- Continued focus on enhancement of our manufacturing capacities and capabilities - investing in a new injectables facility, expanding our larger scale peptide, synthetic and non-immunosuppressant API manufacturing capacities
- In February, our API manufacturing facility in Bengaluru underwent an EU GMP inspection with no critical or major observations. US FDA pre-approval inspection in Hyderabad concluded on 19-May-23 with no observations

In INR Cr	Q4 FY23	Q4 FY22	YoY %
Segment Revenue	717	717	0
PBT	75	116	(35)
% of revenue	10%	16%	

In INR Cr	FY23	FY22	YoY %
Segment Revenue	2,637	2,341	13
PBT	264	261	1
% of revenue	10%	11%	

Biosimilars: Q4 and full year FY23 Update

KEY HIGHLIGHTS

- Q4 FY23 is the first full quarter with consolidated financials having both base and acquired business; guidance met
- R&D investments increased to ₹889 Crores; bDenosumab, bUstekinumab and bPertuzumab undergoing clinical trials
- Restructured vaccines alliance with Serum, withdrawing the issuance of 15% stake in BBL
- 35+ new launches in FY23, increasing reach of BBL products
- Market share for Fulphila and Semglee in US at 14% and 12%, respectively
- Malaysia site inspection by US FDA in Q2 FY24

In INR Cr	Q4 FY23	Q4 FY22	YoY %
Revenue	2,102	982	114
Core EBITDA	742	382	95
% of revenue	39%	39%	
EBITDA	573	257	123
PBT <i>(before exceptions)</i>	152	144	5
% of revenue	7%	15%	

In INR Cr	FY23	FY22	YoY %
Revenue	5,584	3,464	61
Core EBITDA	2,216	1,320	68
% of revenue	41%	39%	
EBITDA	1,338	1,013	32
PBT <i>(before exceptions)</i>	403	543	(26)
% of revenue	7%	16%	

Novels : Q4 FY23 update

KEY HIGHLIGHTS

- Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study)
- Pivotal Phase 1b clinical study of itolizumab for Lupus Nephritis (EQUALISE study) remains on track, top line data expected in 1H2024
- BCA101 is currently in Phase1/1b clinical development in head and neck cancer
- Bicara completed USD 108 million series B financing – fund raise to help advance its lead program BCA101



*Acute Graft-Versus-Host Disease

Research Services: Q4 & full year FY23 update

KEY HIGHLIGHTS

- **Biggest quarter ever. Strong growth with positive performances across all four divisions**
- **The growth of Discovery Services and Dedicated Centers remained steady. The Discovery Services research facility in Hyderabad continued to expand and now houses approximately 900 scientists**
- **Growth in Development Services was driven predominantly by further orders from existing clients**
- **Manufacturing Services continued to support the long-term partnership with Zoetis, following the successful regulatory inspections by the U.S, European and U.K. regulatory authorities**

In INR Cr	Q4 FY23	Q4 FY22	YoY %
Segment Revenue	994	758	31
PBT	231	179	29%
% of revenue	23%	24%	

In INR Cr	FY23	FY22	YoY %
Segment Revenue	3,193	2,604	23
PBT	594	515	15
% of revenue	19%	20%	

- **Delivered full-year results ahead of upgraded guidance,**
- **FY23 delivered the highest absolute year-on-year increase in revenue and EBITDA in the last 5 years**

**Environment,
Social,
Governance**



ESG: A Culture of Purpose, Ethics & Equity

Going beyond financials to have a positive impact

Our ESG Strategy Pillars



Improve access to high quality therapeutics to drive 'Patient Equity'



Build an empowering and inclusive workplace creating 'People Equity'



Adapting to a sustainable business operations for 'Environment Equity'



Operate with integrity, transparency and accountability ensuring 'Stakeholder Equity'



Enable underserved communities 'Social Equity'

Monitor Performance → Improve Through Initiatives → Report Outcomes

Recognitions




Published 1st GRI aligned ESG & BRSR Report for FY22



Improved ESG score of 52, part of Emerging Markets Index & 2023 Sustainability Yearbook



Maintained score of 'B' in 2022 for Water Security



Secured 'Silver' place and improved score to 66 in 2022.



Ranked #8 by Science Magazine – Top Global Pharma & Biotech Employers in 2022



Top 10 - India's Best Workplaces in Diversity, Equity and Inclusion, 2021

Annexures



Biocon's Evolution: Our journey over the last 5 decades

Metamorphosis from manufacturer of enzymes to a vertically integrated bio-pharmaceutical player and global CRO & CDMO of global standing. Created tangible differentiators for sustainable growth with focus on research and innovation

1970s-80s

Innovating Enzyme Technologies

- Incorporated as a joint venture with an Irish biotech (1978)
- Transformed into an export-driven enzymes company
- JV partner acquired by Unilever Plc., Biocon starts producing enzymes for Unilever's food businesses (1989)

1990s

Entry into Research Services and Biopharmaceuticals

- Incorporated Syngene as a custom research organization (1994)
- Scaled up R&D and fermentation capacity, entered biopharmaceutical manufacturing
- Became an independent, privately-owned company

2000s

Transitioning to a biopharmaceutical enterprise

- Established Clinical arm (2000). Entered biologicals manufacturing incl .Novels (2002)
- Unlocked value through IPO, 2nd Indian company to be listed with \$1Bn+ valuation (2004)
- Divested Enzymes business to increase focus on Biopharmaceuticals (2007)
- Partnered with Mylan (now Viatris) for global development, early entry into biosimilars (2009)

2010s

Building Scale for Global Impact

- Invested in R&D, commercial scale, globally compliant manufacturing facilities
- Forward integrated small molecule APIs to formulations
- Syngene listed separately, emerging as India's leading CDMO (2015)
- Ranked in world's Top 15 biomanufacturing cos, partnered with Sandoz for next gen biosimilars

2020+

Building a Company of the Future

- Portfolio and geographical expansions, capacity additions in Generics
- Acquisition of Viatris' Biosimilar business for vertical integration; partnership with Serum for entry to vaccines
- Research Services evolves to a full fledged global CRO & CDMO
- Continued investment in novel innovations & promoting health equity

With many firsts, Biocon is ahead of the curve

- 1st Indian Life Sciences Company to get ISO 9001 Certification

1993

- 1st Clinical Research Service Organization in India established - Clinigene

2000

- 1st company globally to get U.S. FDA approval for making Lovastatin API through innovative fermentation technology.

2001

- 1st company in the world to develop & commercialize Pichia-based rh-Insulin

2004

- 1st Indian Company to launch a novel biologic, Nimotuzumab for head and neck cancer patients

2006

- 1st anti-CD6 monoclonal antibody in the world, Itolizumab, commercialised in India

2013

- 1st company to introduce biosimilar Trastuzumab in the world

2014

- 1st company from India to have a biosimilar approved in Japan

2016

- 1st company globally to receive U.S. FDA approval for biosimilar Trastuzumab

2017

- 1st company to launch Fulphila™, biosimilar Pegfilgrastim in U.S.

2018

- 1st company from India to have a biosimilar commercialized in the US

2018

- 1st company to receive interchangeability designation for a biosimilar (insulin glargine) in the US

2021

Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

**Thank
You**

